MedTrace Logo

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03759704 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-04-04

No results posted yet for this study

Summary

Investigators will determine whether MRSI using hyperpolarized \[1-13C\]pyruvate provide useful information of tumor malignancy in MRI-indeterminate cases. Metabolite maps of hyperpolarized \[1-13C\]lactate and H13CO3- produced from hyperpolarized \[1-13C\]pyruvate will be compared to the biopsy results of MRI-indeterminate patients and the 13C-maps of age-matched healthy subjects.

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Hyperpolarized 13CPyruvate

Bolus injection of study drug during MRSI.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-08-26
Completion
2021-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03759704 on ClinicalTrials.gov